Murine Glioblastoma Xenograft Model
Objective: In vivo assessment of TanCAR T cell efficacy in mitigating antigen escape, enhancing antitumor activity, and improving survival in a murine glioblastoma model
This is a Murine Glioblastoma Xenograft Model protocol using mouse as the model organism. The procedure involves 5 procedural steps. Extracted from a 2016 paper published in Journal of Clinical Investigation.
Model and subjects
mouse • Not specified in provided text • unknown • Not specified in provided text • Not specified in provided text
Study window
Estimated timing pending
Core workflow
Murine Glioblastoma Model Establishment • TanCAR T Cell Administration • Assessment of Antigen Escape Mitigation
Primary readouts
- Mitigation of antigen escape
- Antitumor efficacy
- Animal survival
- Tumor burden reduction
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Murine Glioblastoma Model Establishment
Establish a murine glioblastoma xenograft model for in vivo assessment of TanCAR T cell efficacy
Note: This is a preclinical model used to test antigen escape mitigation and antitumor activity
View evidence from paper
“In a murine glioblastoma model, TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival”
TanCAR T Cell Administration
Administer TanCAR T cells to tumor-bearing mice to assess therapeutic efficacy
Note: TanCAR T cells target both HER2 and IL13Rα2 antigens simultaneously
View evidence from paper
“TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2”
Assessment of Antigen Escape Mitigation
Monitor and measure the ability of TanCAR T cells to mitigate antigen escape variants during tumor progression
Note: Antigen escape variants can lead to tumor recurrence after CAR T cell treatment targeting single antigens
View evidence from paper
“In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence after treatment with CAR T cells”
Measurement of Antitumor Activity
Evaluate enhanced antitumor efficacy of TanCAR T cells in the murine glioblastoma model
Note: TanCAR T cells exhibited enhanced antitumor activity compared to control treatments
View evidence from paper
“TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival”
Survival Assessment
Monitor and record animal survival outcomes following TanCAR T cell treatment
Note: Survival improvement is a primary outcome measure in this in vivo model
View evidence from paper
“TanCAR T cells mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival”